ClearCut Medical Announces Results of a Post Marketing ClearCoast™ Study Presented at the San Antonio Breast Cancer Symposium

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

ClearCut-Medical

More Like This

Dr. Mariana-Felicia Sandor, first author of the SHIELD study: Reoperation Rate in Breast-Conserving Surgery using Confocal Histolog® Scanner for Intraoperative Tissue Assessment, performs real-time, high-resolution tissue assessments during breast-conserving surgery (BCS) using the FDA-cleared Histolog Scanner. SHIELD study data indicates the innovative imaging device reduced reoperation rates during BCS from 30% to 10%, representing a 67% reduction. (Photo: Business Wire)

SamanTree Medical Highlights Research Showing 67% Reduction in Reoperation Rates for Breast-Conserving Surgery at the 2024 SABCS

PR Newswire associated0

New data indicates use of 3D specimen tomosynthesis can improve breast cancer surgical outcomes

PR Newswire associated0

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

ACCLARO MEDICAL TO SHOWCASE INNOVATIVE LASER-CORING APPLICATION OF ITS ULTRACLEAR LASER AT IMCAS 2024, THE PREMIER GLOBAL SCIENTIFIC AESTHETICS CONGRESS

PR Newswire associated0

Innoblative Announces Successful First-in-Human Use of its Novel Electrosurgical Device for Breast Cancer Treatment

PR Newswire associated0

New technology aiming to improve patients' outcomes in breast cancer

New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX® Test on Patient Care and Healthcare Efficiency

New BRAVO Study Publication Reinforces Clinical Benefits of BLC in Reducing Risk of Bladder Cancer Recurrence